3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
4
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
53
Thoracic
10
Gastrointestinal
8
Dermatologic
8
Breast
8
Head & Neck
7
Gynecologic
6
Sarcoma
1
Other solid neoplasm
1
NET
1
Lymphoid
1
Endocrine
1
CNS
1
Conditions
Lymphoma, Non-Hodgkin
767
Lymphoma
713
Leukemia, Lymphocytic, Chronic, B-Cell
560
Lymphoma, Follicular
515
Lymphoma, Large B-Cell, Diffuse
440
Precursor Cell Lymphoblastic Leukemia-Lymphoma
331
Recurrence
317
Lymphoma, B-Cell
294
Neoplasms
261
Lymphoma, Mantle-Cell
251
Leukemia
231
Multiple Myeloma
189
Hodgkin Disease
179
Leukemia, Myeloid, Acute
178
Lymphoma, B-Cell, Marginal Zone
135
Lymphoma, T-Cell, Peripheral
119
Burkitt Lymphoma
105
Myelodysplastic Syndromes
101
Hematologic Neoplasms
100
Lymphoma, T-Cell, Cutaneous
88
Waldenstrom Macroglobulinemia
84
Leukemia, B-Cell
79
Lymphoma, T-Cell
74
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
65
Lymphoproliferative Disorders
57
Hematologic Diseases
57
Melanoma
54
Carcinoma, Non-Small-Cell Lung
54
Breast Neoplasms
51
Mycosis Fungoides
49
Interventions
pembrolizumab
1
GSK-3326595
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Urologic Neoplasms
×
Lymphoid
×
Clear all
NCT02783300
2025-03-10
Meteor 1
GlaxoSmithKline
Phase 1
Completed
297 enrolled
76 charts